RidkerPMDanielsonEFonsecaFAH. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008; 359:2195–207.
2.
RidkerPMRifaiNClearfieldM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med2001; 344:1959–65.
3.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA1998; 279:1615–22.
4.
AmarencoPLabreucheJ. Lipid management and stroke. Lancet Neurol2009; 8:453–63.
5.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005; 366:1267–78 (Erratum in: Lancet2005; 366:1358, and Lancet2008; 371:2084).
6.
ZachoJTybjaerg-HansenAJensenTSGrandePSillesenHNordest-gaardBG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med2008; 359:1897–908.
